Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology.

The current number of 9422 symbols for human gene names (http://www.gene.ucl.ac.uk/nomenclature/) is expected to increase 7- to 15-fold over the next 2 years. In and around each gene, a tremendous degree of single-nucleotide polymorphism (SNP) heterogeneity is now realized to exist. This review is intended to be visionary, to point out some of the enormously complex nomenclature issues that we face, and to offer some reasonable solutions to these issues. For example, I believe that a 'gene' should be defined as that region from the furthest 5'-ward enhancer to at least 150 bases downstream of the last exon. Just as established rules are critically important for the systematic naming of all new genes, standardized nomenclature rules for the naming of allelic variants are also desperately needed. The evolving consensus for naming the alleles of all human genes (ideally based on evolutionarily diverging haplotype patterns) is described herein. Because of the anticipated explosion in finding new genes and allelic variants due to high-throughput resequencing and DNA-chip technologies, this excess of new knowledge will undoubtedly overwhelm their publication by scientific journals alone. I suggest that the best approach to this staggering 'information overload' is to place the data on appropriate web sites--with numerous links between sites, and frequent updates of all information--so that colleagues in all fields of medical and genetic research can remain knowledgeable. Examples of successful web sites to date include those for the cytochrome P450 (CYP) genes and human CYP alleles, UDP glycosyltransferase (UGT) genes and human alleles, human N-acetylaminotransferase (NAT2, NAT1) alleles, and aldehyde dehydrogenase (ALDH) genes and human alleles. Many more web sites will be necessary. For each site, the webmaster will need to be responsible, accurate, energetic, highly organized, and keen to keep the site current. I believe that interactive discussions on these sites should be encouraged, and advisory committees must be willing to check frequently to ensure that all new information is accurate. Lastly, for the field of molecular epidemiology, the importance of correlating an informative genotype with an unequivocal phenotype is emphasized, and the emerging realization that racial and ethnic groups are highly admixed is summarized and updated.

[1]  M. Boehnke,et al.  Loss of information due to ambiguous haplotyping of SNPs , 1999, Nature Genetics.

[2]  C. Nusbaum,et al.  Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. , 1998, Science.

[3]  F. Guengerich,et al.  Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. , 1996, Cancer research.

[4]  M. Ingelman-Sundberg,et al.  Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. , 1999, Drug metabolism reviews.

[5]  J. Eisman,et al.  Prediction of bone density from vitamin D receptor alleles , 1994, Nature.

[6]  G. Dover.  Molecular drive in multigene families: How biological novelties arise, spread and are assimilated , 1986 .

[7]  Nebert Dw.  Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? , 1997, American journal of human genetics.

[8]  P. Malloy,et al.  Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. , 1998, Biochemical and biophysical research communications.

[9]  L. Excoffier,et al.  Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. , 1992, Genetics.

[10]  N. Morton,et al.  Allelic association between marker loci. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Rieder,et al.  Sequence variation in the human angiotensin converting enzyme , 1999, Nature Genetics.

[12]  D. Nebert,et al.  Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? , 1999, Clinical genetics.

[13]  Melanie E. Goward,et al.  The DNA sequence of human chromosome 22 , 1999, Nature.

[14]  L. M. Smith,et al.  Stable-isotope-assisted MALDI-TOF mass spectrometry for accurate determination of nucleotide compositions of PCR products. , 1999, Analytical chemistry.

[15]  N. Shen,et al.  Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis , 1999, Nature Genetics.

[16]  B. Birren,et al.  Campomelic dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9: evidence for an extended control region. , 1999, American journal of human genetics.

[17]  Timothy C. Cox,et al.  Identification and Characterization of a Conserved Erythroid-specific Enhancer Located in Intron 8 of the Human 5-Aminolevulinate Synthase 2 Gene* , 1998, The Journal of Biological Chemistry.

[18]  Jeffrey W. Roberts,et al.  Mechanism of intrinsic transcription termination and antitermination. , 1999, Science.

[19]  D. Nebert,et al.  Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. , 1990, Trends in genetics : TIG.

[20]  T. Ley,et al.  An enhancer element lies 3′ to the human A gamma globin gene. , 1987, The EMBO journal.

[21]  Steven M. Horvath,et al.  Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.

[22]  H. Harris,et al.  Polymorphism and the subunit structure of enzymes: a contribution to the neutralist-selectionist controversy. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Jack A. Taylor,et al.  Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). , 1999, Carcinogenesis.

[24]  N. Cairns,et al.  α-2 macroglobulin polymorphism and Alzheimer disease risk in the UK , 1999, Nature Genetics.

[25]  U. Meyer.  Pharmacogenetics: the slow, the rapid, and the ultrarapid. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Nelson,et al.  Cytochrome P450 and the individuality of species. , 1999, Archives of biochemistry and biophysics.

[27]  M. King,et al.  Genomic Views of Human History , 1999 .

[28]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[29]  M. Ingelman-Sundberg,et al.  In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. , 1997, Biochemical and biophysical research communications.

[30]  S. Tishkoff,et al.  Estimating European admixture in African Americans by using microsatellites and a microsatellite haplotype (CD4/Alu) , 1999, Human Genetics.

[31]  E. Boerwinkle,et al.  DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene , 1998, Nature Genetics.

[32]  J. Trapman,et al.  Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. , 1997, American journal of human genetics.

[33]  H. Harris,et al.  Average heterozygosity per locus in man: an estimate based on the incidence of enzyme polymorphisms , 1972, Annals of human genetics.

[34]  G. Mayr,et al.  A Novel Intron Element Operates Posttranscriptionally To Regulate Human N-mycExpression , 1999, Molecular and Cellular Biology.

[35]  K. Kawajiri,et al.  High Susceptibility to Lung Cancer Analyzed in Terms of Combined Genotypes of P450IA1 and Mu‐class Glutathione S‐Transferase Genes , 1992, Japanese journal of cancer research : Gann.

[36]  J. Shapiro.  Genome System Architecture and Natural Genetic Engineering in Evolution , 1999, Annals of the New York Academy of Sciences.

[37]  Magnus Jobs,et al.  Dynamic allele-specific hybridization , 1999, Nature Biotechnology.

[38]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[39]  A. Clark,et al.  Inference of haplotypes from PCR-amplified samples of diploid populations. , 1990, Molecular biology and evolution.

[40]  J. Haines,et al.  An α-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease , 1999, Nature Genetics.

[41]  D. Baltimore,et al.  A novel, inducible and T cell‐specific enhancer located at the 3′ end of the T cell receptor alpha locus. , 1989, The EMBO journal.

[42]  T. Niu,et al.  An extreme-sib-pair genome scan for genes regulating blood pressure. , 1999, American journal of human genetics.

[43]  Ali Shilatifard,et al.  Factors regulating the transcriptional elongation activity of RNA polymerase II , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  E. Boerwinkle,et al.  Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. , 1998, American journal of human genetics.

[45]  P Belgrader,et al.  Discrimination of single-nucleotide polymorphisms in human DNA using peptide nucleic acid probes detected by MALDI-TOF mass spectrometry. , 1997, Analytical chemistry.

[46]  P. Ross,et al.  High level multiplex genotyping by MALDI-TOF mass spectrometry , 1998, Nature Biotechnology.

[47]  E Lai,et al.  A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. , 1998, Genomics.

[48]  B. Levy-Wilson,et al.  Hepatocyte nuclear factor 1 and C/EBP are essential for the activity of the human apolipoprotein B gene second-intron enhancer , 1992, Molecular and cellular biology.

[49]  T. Griffin,et al.  Direct genetic analysis by matrix-assisted laser desorption/ionization mass spectrometry. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. King,et al.  Evolution at two levels in humans and chimpanzees. , 1975, Science.

[51]  S. Bulun,et al.  Expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  M. Owen,et al.  α-2 macroglobulin gene and Alzheimer disease , 1999, Nature Genetics.

[53]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations , 1998 .

[54]  D. Nebert.  Pharmacogenetics: 65 candles on the cake , 1997 .

[55]  Henrik Kaessmann,et al.  DNA sequence variation in a non-coding region of low recombination on the human X chromosome , 1999, Nature Genetics.

[56]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[57]  G. Cooper,et al.  Are vitamin D receptor polymorphisms associated with bone mineral density? A meta‐analysis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.